TLO - Delayed Quote EUR

Organon & Co. (4OGN.TI)

7.80

-0.15

(-1.94%)

At close: May 6 at 9:40:25 AM GMT+2

Why Organon (OGN) Could Beat Earnings Estimates Again

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks last month

OGN
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

JERSEY CITY, N.J., April 01, 2025--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion.

Business Wire last month

OGN
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

SHANGHAI, China & JERSEY CITY, N.J., March 28, 2025--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire last month

OGN
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

JERSEY CITY, N.J., March 08, 2025--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA® (tapinarof) cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema. The findings demonstrate that AD disease activity remained mild in patients who had achieved treatment success and subsequently en

Business Wire 2 months ago

OGN
Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Organon & Co.'s ( NYSE:OGN ) investors are due to receive a payment of $0.28 per share on 13th of March. Based on this...

Simply Wall St. 2 months ago

OGN
Organon Full Year 2024 Earnings: EPS Misses Expectations

Organon ( NYSE:OGN ) Full Year 2024 Results Key Financial Results Revenue: US$6.40b (up 2.2% from FY 2023). Net income...

Simply Wall St. 2 months ago

OGN
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

JERSEY CITY, N.J., February 13, 2025--Organon announces Q4 2024 and Full Year 2024 earnings results, ending December 31, 2024.

Business Wire 2 months ago

OGN
An excellent week for Organon & Co.'s (NYSE:OGN) institutional owners who own 83% as one-year returns inch higher

Key Insights Given the large stake in the stock by institutions, Organon's stock price might be vulnerable to their...

Simply Wall St. 3 months ago

OGN
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

JERSEY CITY, N.J., January 23, 2025--Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Business Wire 3 months ago

OGN
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J., December 19, 2024--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th

Business Wire 4 months ago

OGN
FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

Organon (OGN) announced that the U.S. Food and Drug Administration or FDA has approved VTAMA or tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis AD in adults and pediatric patients 2 years of age and older.Organon received the FDA approval prior to its extended target action date PDUFA of March 12. “With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there

TipRanks 4 months ago

OGN
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

JERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a first-in-class therapy with new FDA approval for atopic dermatitis in adults and children aged 2 and older.

Business Wire 4 months ago

OGN
Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found some...

Simply Wall St. 5 months ago

OGN
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Organon & Co. ( NYSE:OGN ) shareholders are probably feeling a little disappointed, since its shares fell 3.1% to...

Simply Wall St. 6 months ago

OGN
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

JERSEY CITY, N.J., November 05, 2024--The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Business Wire 6 months ago

OGN
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Organon & Co.'s ( NYSE:OGN ) investors are due to receive a payment of $0.28 per share on 12th of December. Based on...

Simply Wall St. 6 months ago

OGN
Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon ( NYSE:OGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.58b (up 4.1% from 3Q 2023). Net...

Simply Wall St. 6 months ago

OGN
Organon Reports Results for the Third Quarter Ended September 30, 2024

JERSEY CITY, N.J., October 31, 2024--Organon Reports Q3 2024 Earnings

Business Wire 6 months ago

OGN
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

SHANGHAI, China & JERSEY CITY, N.J., October 30, 2024--Henlius and Organon announced US FDA has accepted the Biologics License Application (BLA) for HLX14, biosimilar candidate of PROLIA/XGEVA (denosumab).

Business Wire 6 months ago

2696.HK

OGN
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to developing and commercializi

GlobeNewswire 6 months ago

ROIV

OGN

Performance Overview

Return	4OGN.TI	MSCI WORLD (^990100-USD-STRD)
YTD	-44.76%	+0.10%
1-Year	-56.61%	+8.53%
3-Year	-71.51%	+39.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Organon & Co. (4OGN.TI)

Why Organon (OGN) Could Beat Earnings Estimates Again

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Organon Full Year 2024 Earnings: EPS Misses Expectations

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

An excellent week for Organon & Co.'s (NYSE:OGN) institutional owners who own 83% as one-year returns inch higher

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon Reports Results for the Third Quarter Ended September 30, 2024

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Performance Overview